T
igecycline is the prototype compound of the new class of broad-spectrum antimicrobial agents known as glycylcyclines (1, 2) . Tigecycline was initially approved by the U.S. Food and Drug Administration (FDA) in 2005 for the treatment of adults with complicated skin and skin structure infections (cSSSIs) and complicated intra-abdominal infections (cIAIs) (3) . In 2009, tigecycline also received FDA approval for treatment of communityacquired bacterial pneumonia (1, 3) . This minocycline derivative has provided clinicians with an alternative option for infections caused by difficult-to-treat pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus spp. (VRE), Enterobacteriaceae strains that produce extended-spectrum ␤-lactamases (ESBLs) and carbapenemases, such as Klebsiella pneumoniae carbapenemases (KPCs) and metallo-␤-lactamases, and multidrug-resistant (MDR) Acinetobacter spp. (4) (5) (6) (7) (8) (9) .
Data from surveillance monitoring programs such as the SENTRY Antimicrobial Surveillance Program have provided information on the continuing activity of tigecycline against a wide spectrum of clinically important Gram-positive and Gram-negative bacteria over time (8, 10) . To understand the evolution of the in vitro activity of tigecycline since the initial approval of tigecycline for clinical use, we analyzed the results for 7 years (2006 to 2012) of the U.S. SENTRY Program. We also assessed changes in the prevalence of clinically important resistance phenotypes with time.
MATERIALS AND METHODS

Bacterial isolates.
A total of 68,608 unique clinical isolates were consecutively collected from 29 medical centers distributed in 21 states throughout all nine U.S. Census regions. The vast majority of medical centers participated in the 7 years of the study. The isolates were collected between January 2006 and December 2012, except for Streptococcus pneumoniae and Haemophilus influenzae, which were collected between January 2010 and December 2012. Species identification was performed by the participating centers and confirmed at JMI Laboratories (North Liberty, IA), when necessary, by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) using a Bruker Daltonics MALDI Biotyper (Billerica, MA), following the manufacturer's instructions. Isolates were from clinically significant infections from patients with bloodstream infections (46%), wound or skin and skin structure infections (22%), pneumonia (in hospitalized patients) (16%), community-acquired respiratory tract infections (7%), urinary tract infections (5%), or other infection types (4%).
Susceptibility testing. Isolates were tested for susceptibility to multiple antimicrobial agents at a central reference laboratory (JMI Laboratories, North Liberty, IA) by reference broth microdilution methods, as described by the Clinical and Laboratory Standards Institute (CLSI) (11), using validated broth microdilution panels produced by Thermo Fisher Scientific, Inc. (formerly TREK Diagnostics, Cleveland, OH). MIC results were interpreted according to CLSI criteria (12) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint tables (version 3.0, January 2013) (http://www.eucast.org/clinical_breakpoints). Tigecycline MIC breakpoints were those found in the U.S. FDA-approved package insert (3). Vancomycin-resistant enterococci (VRE) were defined on the basis of a vancomycin MIC of Ն8 g/ml, i.e., nonsusceptible by CLSI criteria (12) and resistant by EUCAST criteria (http://www.eucast.org/clinical_breakpoints). Escherichia coli and Klebsiella isolates were grouped as the extended-spectrum ␤-lactamase (ESBL) phenotype based on the CLSI screening criteria for potential ESBL production, i.e., MIC of Ն2 g/ml for ceftazidime, ceftriaxone, or aztreonam (12) . Although an ESBL confirmation test was not performed and other ␤-lactamases, such as AmpC and K. pneumoniae carbapenemases (KPCs), may also produce an ESBL phenotype, these strains were grouped together because they usually demonstrate resistance to various broad-spectrum ␤-lactam compounds. Meropenemnonsusceptible Klebsiella spp. indicates a meropenem MIC of Ն2 g/ml. Multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) bacteria were classified as such according to recently recommended guidelines (13) , using the following antimicrobial classrepresentative agents and CLSI interpretive criteria (12): ceftriaxone, Ն2 g/ml; meropenem, Ն2 g/ml; piperacillin-tazobactam, Ն32/4 g/ml; levofloxacin, Ն4 g/ml; gentamicin, Ն8 g/ml; tigecycline, Ն4 g/ml; colistin, Ն4 g/ml. Classifications were based on the following recommended parameters: MDR, nonsusceptible to Ն1 agent in Ն3 antimicrobial classes; XDR, nonsusceptible to Ն1 agent in all but Յ2 antimicrobial classes; PDR, nonsusceptible to all antimicrobial classes (13) . Quality control (QC) was performed according to CLSI methods (12) using (i) Escherichia coli ATCC 25922 and 35218, (ii) Staphylococcus aureus ATCC 29213, (iii) Pseudomonas aeruginosa ATCC 27853, and (iv) Enterococcus faecalis ATCC 29212. All QC results were within the published range (12) .
Statistical analysis. The chi-square test for trend was applied to assess the yearly trends of resistance phenotypes. Statistical analyses were performed with the Epi Info 7 statistical package. P values of Ͻ0.05 were considered significant.
RESULTS
The in vitro activities of tigecycline tested against clinical bacteria collected during the 7-year period (2006 to 2012) of the study are summarized in the form of MIC distributions (Table 1) . Tigecycline was highly active against Gram-positive organisms, with MIC 50 and MIC 90 values of 0.12 and 0.25 g/ml, respectively, for S. aureus (28,278 strains), 0.06 to 0.12 and 0.12 to 0.25 g/ml for enterococci (E. faecalis [4, (Table 1) .
Among the 20,457 Enterobacteriaceae strains evaluated, tigecycline MIC 50 and MIC 90 values were 0.25 and 1 g/ml, respectively, and 98.3% of the strains were considered susceptible according to the U.S. FDA breakpoint criterion of Յ2 g/ml (12) . The most tigecycline-susceptible Enterobacteriaceae species was E. coli (MIC 50 , 0.12 g/ml; MIC 90 , 0.25 g/ml; 100.0% susceptible), followed by Klebsiella spp., Enterobacter spp., and Citrobacter spp. (MIC 50 and MIC 90 values of 0.25 and 1 g/ml, respectively, for all three genera; 98.6 to 99.9% susceptible) ( Table 1) . Tigecycline was particularly active against MDR (MIC 50 , 0.12 g/ml; MIC 90 , 0.25 g/ml; 90.1% susceptible) and XDR (MIC 50 , 2 g/ml; MIC 90 , 4 g/ml; 85.3% susceptible) Enterobacteriaceae strains. No PDR Enterobacteriaceae strains were observed. The least tigecycline-sus- ceptible Enterobacteriaceae species or groups were Proteus mirabilis (MIC 50 , 2 g/ml; MIC 90 , 4 g/ml) and indole-positive Proteae (MIC 50 , 0.5 g/ml; MIC 90 , 2 g/ml), which are not listed as indicated species (3). Tigecycline also showed activity against Acinetobacter spp. (MIC 50 , 0.5 g/ml; MIC 90 , 2 g/ml), Stenotrophomonas maltophilia (MIC 50 , 0.5 g/ml; MIC 90 , 2 g/ml), and H. influenzae (MIC 50 , 0.12 g/ml; MIC 90 , 0.25 g/ml) ( Table 1) . The prevalence of tigecycline-nonsusceptible strains was extremely low among Gram-positive species, with the highest rate being observed among E. faecium (0.7% nonsusceptible), followed by E. faecalis (0.4%), S. pneumoniae (Ͻ0.1%), and S. aureus (Ͻ0.1%) ( Table 2) . Among Enterobacteriaceae strains, 1.7% of strains were categorized as nonsusceptible (intermediate, 1.6%; resistant, 0.1%), and nonsusceptibility rates were higher among MDR (9.9%) and XDR (14.7%) strains. Most importantly, no trend toward increased tigecycline resistance was observed for any species or group during the study period (2006 to 2012) ( Table 2 ).
The activities of tigecycline and selected comparator agents for S. aureus, E. faecalis, E. faecium, and Enterobacteriaceae, including the MDR and XDR subsets, were analyzed (Table 3) . Tigecycline, daptomycin, linezolid, and vancomycin were active against Ն99.9% of S. aureus strains, whereas tigecycline (MIC 50 , 0.12 g/ ml; MIC 90 , 0.25 g/ml) was 2-fold more active than daptomycin (MIC 50 , 0.25 g/ml; MIC 90 , 0.5 g/ml) and 8-fold more active than linezolid (MIC 50 , 1 g/ml; MIC 90 , 2 g/ml) and vancomycin (MIC 50 , 1 g/ml; MIC 90 , 1 g/ml) when tested against this large collection of S. aureus strains (Table 3) . Tigecycline was also the most potent (by weight) agent tested against E. faecalis (MIC 50 , 0.12 g/ml; MIC 90 , 0.25 g/ml; 99.6% susceptible) and E. faecium (MIC 50 , 0.06 g/ml; MIC 90 , 0.12 g/ml; 99.3% susceptible). Daptomycin was also very active against both E. faecalis (MIC 50 , 1 g/ml; MIC 90 , 1 g/ml; Ͼ99.9% susceptible) and E. faecium (MIC 50 , 2 g/ml; MIC 90 , 2 g/ml; 99.6% susceptible), whereas ampicillin exhibited good activity against E. faecalis (MIC 50 , Յ1 g/ml; MIC 90 , 2 g/ml; 99.9% susceptible) but not against E. faecium (MIC 50 , Ͼ8 g/ml; MIC 90 , Ͼ8 g/ml; 7.5% susceptible). Vancomycin susceptibility rates were 95.4 and 23.5% for E. faecalis and E. faecium, respectively (Table 3) .
Tigecycline (MIC 50 , 0.25 g/ml; MIC 90 , 1 g/ml), amikacin (MIC 50 , Յ4 g/ml; MIC 90 , Յ4 g/ml), and meropenem (MIC 50 , Յ0.12 g/ml; MIC 90 , Յ0.12 g/ml) were the most active compounds tested against Enterobacteriaceae strains overall, with susceptibility rates of 98.3 to 98.6%. The MDR and XDR subsets showed high rates of resistance to most agents, including amikacin (82.7 and 59.8% susceptible, respectively) and meropenem (75.0 and 20.5% susceptible, respectively). Tigecycline was the most active agent against these difficult-to-treat organisms, with susceptibility rates of 90.1 and 85.3% for MDR and XDR strains, respectively ( Table 3) .
The yearly prevalence of key resistance phenotypes is presented in Table 4 , which shows an increase in all resistance phenotypes except for methicillin resistance among S. aureus isolates and vancomycin resistance among E. faecalis isolates. The prevalence of MDR and XDR Enterobacteriaceae escalated from 4.4 and 0.5%, (16) . Historically, it has taken only a few years following clinical introduction of an antimicrobial agent for resistance to emerge and to increase rapidly. However, the results of this investigation indicate that tigecycline nonsusceptibility remains rare after several years of clinical use, providing potent empirical coverage against MRSA in U.S. medical centers (17) .
Tigecycline was also remarkably active against E. faecalis and E. faecium, including vancomycin-resistant strains, for which very few therapeutic options are available (18) . The optimal treatment of systemic VRE infections has not been well established due to the lack of prospective outcome studies comparing available treatment options (19) . Due to its potent in vitro activity, tigecycline represents an attractive therapeutic option; however, further clinical data are necessary to establish the role of tigecycline in the treatment of VRE infections (20) . It is also important to note that tigecycline is not approved by the U.S. FDA for treatment of VRE infections; it is approved only for treatment of cSSSIs and cIAIs caused by vancomycin-susceptible E. faecalis (3) .
Some of the most noteworthy findings of this investigation were the significant increases in the prevalence of important resistance phenotypes among Enterobacteriaceae. ESBL phenotype rates doubled among E. coli and Klebsiella spp., whereas the prevalence of meropenem-nonsusceptible K. pneumoniae increased 5-fold (from 2.2 to 10.8%) between 2006 and 2012. Furthermore, the prevalence of MDR and XDR Enterobacteriaceae increased 2-to 3-fold during the same period (Table 4) . MDR Enterobacteriaceae strains were observed in 26 of 29 medical centers evaluated, which were distributed across 21 states, whereas XDR strains were detected in 15 medical centers in 9 states. Although carbapenemresistant, MDR, and XDR Enterobacteriaceae strains remain relatively uncommon in most U.S. hospitals, these organisms have become increasingly recognized as causes of infections in the past decade (21, 22) .
There are very few options available for the treatment of infections caused by MDR and XDR Enterobacteriaceae, especially those caused by carbapenem-resistant strains, and severe infections are frequently treated with combination therapy (23) (24) (25) . Kelesidis et al. (7) performed a literature review to assess the in vitro activity of tigecycline against MDR Enterobacteriaceae, as well as the clinical evidence regarding the use of tigecycline for the treatment of infections caused by these organisms. Those authors concluded that tigecycline was microbiologically active (based on U.S. FDA breakpoint criteria) against the great majority of MDR Enterobacteriaceae (3). They also observed that clinical reports were limited and further evaluation of the clinical utility of tigecycline is warranted, particularly regarding off-label indications (7) .
The results of the present study are in agreement with those of other reports in showing that tigecycline is among the agents that retain in vitro activity against MDR and XDR Enterobacteriaceae, Acinetobacter spp., and S. maltophilia (4, 6, 7, 10, 24, 26) . Due to its in vitro activity, tigecycline has been used for the treatment of infections caused by these organisms, especially when alternative treatments are not suitable; however, the role of tigecycline in the treatment of infections caused by MDR Gram-negative organisms is not well established, and further clinical studies are suggested (3, 25, 27) .
In summary, we assessed the progression of the in vitro activity of tigecycline since its initial approval by the U.S. FDA, using a total of 68,608 unique clinical isolates, and tigecycline showed sustained potent activity against clinically important organisms, including MDR subsets of Gram-positive and Gram-negative pathogens. Furthermore, the results of this investigation clearly demonstrated marked increases in the prevalence MDR and XDR Enterobacteriaceae in U.S. hospitals between 2006 and 2012. A large longitudinal surveillance network, such as the SENTRY Program, is a valuable tool for documenting emerging resistance and longitudinal trends.
